Doctors Note Logo

Published on: 9/24/2026

How long does citalopram withdrawal last?

Citalopram withdrawal symptoms, also called discontinuation syndrome, usually begin within 2 to 4 days of stopping or lowering the dose and often ease within 1 to 3 weeks, though some people experience lingering effects for several weeks or months. Common symptoms include dizziness, flu-like fatigue, nausea, irritability, vivid dreams, anxiety, and "brain zaps," and their duration depends on how long you took the drug, your dose, how quickly you tapered, and your individual biology. There are several important factors and warning signs to consider, so see below to understand more about what shortens or prolongs recovery and when symptoms may signal returning depression rather than withdrawal.

Because withdrawal effects can closely mimic relapse, worsening mood disorders, or unrelated conditions, guessing on your own can delay the right care. A free, instant, online symptom check can help you organize what you are feeling, gauge urgency, and prepare clearer questions for your prescriber about tapering or next steps.

Last reviewed for medical accuracy: 09/24/2026

answer background

Explanation

How Long Does Citalopram Withdrawal Last?

Citalopram is a selective serotonin reuptake inhibitor (SSRI) commonly prescribed for depression and anxiety. Though it is not classified as a controlled substance, it is a prescription‐only medication regulated by the FDA. Stopping citalopram too quickly can lead to withdrawal (also called discontinuation syndrome). Understanding what to expect can help you plan a safer taper and manage symptoms if they arise.

What Is Citalopram and Is It a Controlled Substance?

  • Citalopram is an SSRI used to treat major depressive disorder, panic disorder and certain anxiety conditions.
  • Despite the SEO term “citalopram controlled substance,” it is not listed under DEA schedules.
  • It remains a tightly regulated prescription medication that should only be started or stopped under medical supervision.

Why Withdrawal Occurs

Over weeks or months of use, your brain adjusts to higher serotonin levels. Suddenly reducing or stopping citalopram forces your nervous system to rebalance. This shift can trigger a cluster of symptoms known as SSRI discontinuation syndrome.

Typical Timeline for Withdrawal

Exact duration varies, but most people experience symptoms in three overlapping phases:

  1. Early Onset (1–7 days)

    • First symptoms often appear 1–3 days after dose reduction or last dose.
    • Common issues: dizziness, electric-shock “brain zaps,” nausea.
  2. Peak Phase (1–3 weeks)

    • Symptoms generally peak between days 7 and 21.
    • New or intensified symptoms: irritability, mood swings, insomnia.
  3. Resolution or Protracted Phase (3 weeks–several months)

    • Many people see steady improvement by 4–6 weeks.
    • A minority may have milder symptoms lasting 2–3 months or longer.
    • Protracted symptoms are less intense but can still affect quality of life.

Common Withdrawal Symptoms

People can experience a mix of physical and emotional symptoms. Frequent complaints include:

  • Neurological:
    • “Brain zaps” or electric-shock sensations
    • Headaches, dizziness, balance problems
  • Gastrointestinal:
    • Nausea, vomiting, diarrhea
    • Loss of appetite
  • Sleep and Energy:
    • Insomnia or vivid dreams
    • Fatigue, lethargy
  • Mood and Cognition:
    • Irritability, tearfulness
    • Anxiety, restlessness
    • Difficulty concentrating
  • Flu-like:
    • Sweating, chills
    • Muscle aches, tremors

Factors That Influence Withdrawal Duration

Each person’s experience is unique. Key variables include:

  • Dose and Duration
    • Higher doses and longer treatment generally lead to a longer, more intense withdrawal.
  • Tapering Speed
    • Rapid discontinuation (over days) often causes more severe symptoms than a gradual taper (weeks to months).
  • Individual Sensitivity
    • Age, metabolism, medical history and genetics play a role.
  • Concurrent Medications
    • Switching to or adding another SSRI (e.g., fluoxetine) can smooth the process for some people.

Managing Withdrawal Safely

A carefully planned taper is the gold standard for minimizing discontinuation symptoms. Strategies include:

  • Gradual Dose Reduction
    • Reduce by no more than 10–25% of the current dose every 2–4 weeks, based on tolerance.
  • Medical Supervision
    • Work closely with your prescriber. They may recommend slower tapers or temporary dose adjustments.
  • Switching to a Longer-Acting SSRI
    • Some clinicians transition patients to fluoxetine before tapering, due to its longer half-life.
  • Symptom-Targeted Support
    • Over‐the‐counter remedies for headaches or nausea.
    • Sleep hygiene: maintain regular sleep schedule, avoid screens before bed.
    • Gentle exercise, hydration and balanced meals.

When to Seek Professional Help

Most withdrawal symptoms are uncomfortable rather than dangerous. However, reach out to a healthcare provider if you experience:

  • Severe suicidal thoughts or behaviors
  • Intense panic or psychosis
  • Inability to eat or drink for more than 24 hours
  • Signs of severe dehydration (dizziness, low urine output)
  • Any life‐threatening or rapidly worsening symptom

Before making changes to your medication, consider performing a free, online symptom check, using the doctor approved Ubie Symptom Checker.

Tips to Ease the Transition

  • Keep a Symptom Diary: Note what you feel each day to share with your doctor.
  • Stay Connected: Lean on friends, family or support groups.
  • Practice Stress-Reduction: Meditation, deep breathing or yoga can help stabilize mood.
  • Maintain Routine: Regular meals, sleep and activity help your body adjust.

Key Takeaways

  • Citalopram is not a controlled substance but requires a prescription and careful management.
  • Withdrawal symptoms usually start 1–7 days after dose reduction, peak by week 2, and resolve within 4–6 weeks for most people.
  • A slow, supervised taper is the best way to minimize discomfort.
  • Monitor symptoms closely, stay hydrated, practice good sleep habits and seek medical help for any serious concerns.

Always speak to a doctor before stopping or changing your medication—and immediately if you experience anything that could be life-threatening or seriously impacts your wellbeing.

(References)

  • * Burke WJ. Escitalopram. Expert Opin Investig Drugs. 2002 Oct;11(10):1477-86. doi: 10.1517/13543784.11.10.1477. PMID: 12387707.

  • * Ak S, Anıl Yağcıoğlu AE. Escitalopram-induced Parkinsonism. Gen Hosp Psychiatry. 2014 Jan-Feb;36(1):126.e1-2. doi: 10.1016/j.genhosppsych.2013.09.010. Epub 2013 Oct 5. PMID: 24176515.

  • * Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review. Psychother Psychosom. 2015;84(2):72-81. doi: 10.1159/000370338. Epub 2015 Feb 21. PMID: 25721705.

  • * Citalopram. 2006. PMID: 30000244.

  • * Chen A, Copeli F, Metzger E, Cloutier A, Osser DN. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on management of behavioral and psychological symptoms in dementia. Psychiatry Res. 2021 Jan;295:113641. doi: 10.1016/j.psychres.2020.113641. Epub 2020 Dec 13. PMID: 33340800.

  • * Oliva V, Lippi M, Paci R, Del Fabro L, Delvecchio G, Brambilla P, De Ronchi D, Fanelli G, Serretti A. Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13;109:110266. doi: 10.1016/j.pnpbp.2021.110266. Epub 2021 Feb 5. PMID: 33549697.

  • * Lewis G, Marston L, Duffy L, Freemantle N, Gilbody S, Hunter R, Kendrick T, Kessler D, Mangin D, King M, Lanham P, Moore M, Nazareth I, Wiles N, Bacon F, Bird M, Brabyn S, Burns A, Clarke CS, Hunt A, Pervin J, Lewis G. Maintenance or Discontinuation of Antidepressants in Primary Care. N Engl J Med. 2021 Sep 30;385(14):1257-1267. doi: 10.1056/NEJMoa2106356. PMID: 34587384.

  • * Kishi T, Ikuta T, Sakuma K, Okuya M, Hatano M, Matsuda Y, Iwata N. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Mol Psychiatry. 2023 Jan;28(1):402-409. doi: 10.1038/s41380-022-01824-z. Epub 2022 Oct 17. PMID: 36253442; PMCID: PMC9812779.

  • * Sharp T, Collins H. Mechanisms of SSRI Therapy and Discontinuation. Curr Top Behav Neurosci. 2024;66:21-47. doi: 10.1007/7854_2023_452. PMID: 37955823.

  • * Rissardo JP, Fornari Caprara AL, Bhal N, Repudi R, Zlatin L, Walker IM. Drug-Induced Myoclonus: A Systematic Review. Medicina (Kaunas). 2025 Jan 15;61(1). doi: 10.3390/medicina61010131. Epub 2025 Jan 15. PMID: 39859113; PMCID: PMC11767161.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.